Acute Myeloid Leukemia

Idarubicin and etoposide have comparable results to other therapy

Published in Clinical Oncology Week, April 14th, 2003

Idarubicin and etoposide have comparable results to other therapy in acute myeloid leukemia.

According to a study from Spain, "Exploring tolerable regimes for the treatment of acute myeloid leukemia (AML) in elderly patients is of interest.

"Twenty-two adults over 70 years of age with AML were treated with an oral schedule of idarubicin (30 mg/m²/d) and etoposide (45 mg/m²/d) for 3 consecutive days," stated A. Oriol and coauthors, University of Barcelona.

"Seven (32%) achieved complete remission, seven (32%) showed absolute resistance, and eight (36%) died. The survival probability 1 year after diagnosis was...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Oncology Week

Source: Clinical Oncology Week (2003-04-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry